TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Rhea-AI Summary
TransCode Therapeutics (NASDAQ: RNAZ) will host its first live virtual R&D webcast on June 18, 2026, at 10:00–11:15 a.m. Eastern Time. The event will highlight the TTX-MC138 Phase 2a trial in ctDNA-positive colorectal cancer, its three-platform RNA and immuno-oncology pipeline, and overall investment thesis.
The webcast is open access, with registration available on the company website from June 11, 2026. A replay will be posted online after the event.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
RNAZ fell -4.11% with light volume, while at least 2 tracked biotech peers (e.g., APRE, DWTX) also moved down (median around -3.6%), pointing to broader sector pressure rather than a company-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Phase 1a results | Positive | -4.6% | Final Phase 1a safety and stabilization data for TTX-MC138 in metastatic cancer. |
| May 27 | Phase 2a initiation | Positive | -5.6% | Initiation of Phase 2a trial of TTX-MC138 in ctDNA-positive colorectal cancer. |
| Apr 07 | Flexible financing | Positive | -2.9% | Agreements for up to $20M flexible financing to extend runway into 2027/2028. |
| Mar 03 | Oncolytic license deal | Positive | +3.9% | Exclusive license for next-gen oncolytic immunotherapy platform via all-stock deal. |
| Feb 23 | Preclinical publication | Neutral | -0.2% | Peer-reviewed RIG-I agonist preclinical data using TTX nanoparticle platform. |
Recent positive clinical and financing announcements often coincided with negative price reactions, suggesting a pattern of selling into good news.
Over the last few months, TransCode reported final Phase 1a data for TTX-MC138 with no dose-limiting toxicities and durable stable disease, then initiated a Phase 2a trial in ctDNA-positive colorectal cancer. It secured up to $20M in flexible financing to support this program and entered an all-stock deal for an oncolytic immunotherapy platform. A preclinical RIG-I agonist publication further highlighted its TTX nanoparticle platform. The new R&D webcast centers on these advancing programs and the broader three-platform strategy.
Regulatory & Risk Context
An effective S-3 shelf dated April 30, 2026 permits resale of up to 15,955,543 common shares by named selling stockholders. The company is not selling shares under this registration and will not receive proceeds from these resales, though conversions of preferred stock could increase the public float.
Market Pulse Summary
This announcement highlights an R&D webcast on June 18, 2026 to detail the Phase 2a TTX-MC138 trial, the three-platform pipeline, and the company’s investment thesis. In recent months, TransCode advanced TTX-MC138 clinically, secured up to $20M in flexible financing, and added an oncolytic immunotherapy platform, while also addressing Nasdaq equity compliance via proxy proposals. Investors may watch for trial design clarity, timelines, and how management frames capital needs and potential preferred-share conversions.
Key Terms
phase 2a medical
ctdna medical
colorectal cancer medical
antagomir medical
rna therapeutics medical
immuno-oncology medical
AI-generated analysis. Not financial advice.
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis
The webcast will provide strategic, scientific, and clinical program updates anchored by TransCode's recently-initiated Phase 2a clinical trial of TTX-MC138 — the Company's lead antagomiR program — in ctDNA-positive colorectal cancer, alongside portfolio and investment thesis updates across its development pipeline. A recording of the webcast will be made available on the Company's website following the event.
Date: | Thursday, June 18, 2026 |
Time: | 10:00 -11:15 a.m. Eastern Time |
Format: | Live webcast, open access |
Registration: | Will be made available on www.transcodetherapeutics.com as of June 11, 2026 |
Replay: | Webcast recording available on the Company's website following the event |
The webcast will cover:
- TTX-MC138 Phase 2a clinical development, including trial design and strategic path forward
- Pipeline and development strategy across the Company's other candidates and platforms
- Capital strategy, financial position, and long-term investment thesis
Featured speakers will include:
- Guest: Keith Flaherty, MD — Director of Clinical Research, Massachusetts General Hospital Cancer Center; Professor of Medicine, Harvard Medical School; Member, TransCode Scientific Advisory Board
- Philippe P Calais, PharmD, PhD — Chief Executive Officer and Chairman of the Board, TransCode Therapeutics
- Dan Vlock, MD — Consulting Oncology Clinician, TransCode Therapeutics
- Zdravka Medarova, PhD — Co-Founder and Chief Scientific Officer, TransCode Therapeutics
- Louis Brenner, MD — Consulting Strategic Advisor, TransCode Therapeutics
- Michel Janicot, PhD — Consulting Head of Translational Science, TransCode Therapeutics
"With TTX-MC138 now beginning enrollment in Phase 2a, and with two additional platform assets advancing on capital-disciplined timelines, TransCode is at a meaningful inflection point. This webcast is an opportunity to share for the first time in our Company's history the scientific depth behind our programs, review the clinical data that supported our decision to move into the Phase 2a trial, and articulate the investment thesis underlying a three-platform pipeline. We look forward to engaging with our investors and the investment community."
— Philippe P Calais, PharmD, PhD, Chief Executive Officer and Chairman of the Board, TransCode Therapeutics
About TransCode Therapeutics
TransCode Therapeutics is an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the timing, conduct, and anticipated results of TransCode's clinical programs, the therapeutic potential of TTX-MC138, and the Company's development, capital strategy, investment thesis, and communications to the public. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2025, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/transcode-therapeutics-to-host-rd-webcast-on-june-18-2026-302793483.html
SOURCE TransCode Therapeutics, Inc.